Predicting future response to certolizumab pegol in rheumatoid arthritis patients: Features at 12 weeks associated with low disease activity at 1 year

We could accurately predict within 12 weeks of starting CZP whether most established rheumatoid arthritis (RA) patients with high baseline disease activity w...